View source for Pelvic inflammatory disease medical therapy


__NOTOC__
{{Pelvic inflammatory disease}}
{{CMG}};{{AE}}:{{AK}}

==Overview==
Treatments for Pelvic Inflammatory Disease (PID) depend on the cause and generally involve the use of [[antibiotic]] therapy.  If the patient has not improved within two to three days after beginning antibiotic treatment, they should return to the hospital for further treatment.  Drugs should be immediately administered orally and/or intravenously to the patient to increase the effectiveness of antibiotic treatment.   Hospitalization may be necessary if there is tubo-ovarian abscess, if the patient is very ill, immunodeficient, pregnant, incompetent, or if other life threatening events can not be ruled out.  Treating partners for sexually transmitted diseases is a very important part of PID treatment and prevention. Anyone with PID and partners of patients who have been diagnosed with PID in the past six months should be treated to prevent reinfection.  Psychotherapy is highly recommended to women diagnosed with PID as the fear of redeveloping the disease after being cured may exist. It is important for a patient to communicate any issues and/or uncertainties they may have to a doctor, especially a specialist such as a gynecologist, and to seek follow-up care.

==Medical Therapy==
PID can be cured with several types of antibiotics. A health care provider will determine and prescribe the best therapy. However, antibiotic treatment does not reverse any damage that has already occurred to the reproductive organs. If a woman has pelvic pain and other symptoms of PID, it is critical that she seek care immediately. Prompt antibiotic treatment can prevent severe damage to reproductive organs. The longer a woman delays treatment for PID, the more likely she is to become infertile or to have a future ectopic pregnancy because of damage to the [[fallopian tube]]s.

Because of the difficulty in identifying organisms infecting the internal reproductive organs and because more than one organism may be responsible for an episode of PID, PID is usually treated with at least two antibiotics that are effective against a wide range of infectious agents. These antibiotics can be given by mouth or by injection. The symptoms may go away before the infection is cured. Even if symptoms go away, the woman should finish taking all of the prescribed medicine. This will help prevent the infection from returning. Women being treated for PID should be re-evaluated by their health care provider three days after starting treatment to be sure the [[antibiotics]] are working to cure the infection. In addition, a woman’s sex partner(s) should be treated to decrease the risk of re-infection, even if the partner(s) has no symptoms. Although sex partners may have no symptoms, they may still be infected with the organisms that can cause PID.

[[Hospitalization]] to treat PID may be recommended if the woman

(1) Is severely ill (e.g., [[nausea]], [[vomiting]], and high [[fever]])

(2) Is pregnant

(3) Does not respond to or cannot take oral medication and needs intravenous antibiotics

(4) Has an abscess in the [[fallopian tube]] or [[ovary]] (tubo-ovarian abscess) or

(5) Needs to be monitored to be sure that her symptoms are not due to another condition that would require emergency surgery (e.g., [[appendicitis]]).

No evidence is available to suggest that adolescents benefit from hospitalization for treatment of PID. The decision to hospitalize adolescents with acute PID should be based on the same criteria used for older women. Younger women with mild-to-moderate acute PID have similar outcomes with either outpatient or inpatient therapy, and clinical response to outpatient  treatment is similar among younger and older women.

If symptoms continue or if an abscess does not go away, surgery may be needed.

===Empiric Treatment===
Treatment is usually started [[empirical|empirically]] because of the terrible complications. The optimal treatment regimen and long-term outcome of early treatment of women with asymptomatic or subclinical PID are unknown. Diagnosis and management of other common causes of lower abdominal pain (e.g., [[ectopic pregnancy]], acute [[appendicitis]], and functional pain) are unlikely to be impaired by initiating empiric antimicrobial therapy for PID.

Empiric treatment for PID should be initiated in sexually active young women and other women at risk for STDs if they are experiencing pelvic or lower abdominal pain, if no cause for the illness other than PID can be identified, and if one or more of the following minimum criteria are present on pelvic examination:

* [[Cervix|Cervical]] motion tenderness
or
* [[Uterus|Uterine]] tenderness
or
* Adnexal tenderness.

;Shown below is a table summarizing the preferred and alternative empiric treatment for Pelvic inflammatory disease (includes [[salpingitis]], tubo-ovarian abscess and [[pelvic peritonitis]]).


{| style="background: #FFFFFF;"
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|PID TREATMENT}}
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #4479BA;" align=center | '''''Outpatient'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 250 mg IM or IV x 1 dose'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metronidazole]] 500 mg po bid x 14 days'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Doxycycline]] 100 mg po bid x 14 days'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefoxitin]] 2 gm IM with [[Probenecid]] 1 gm po both as single dose''''' 
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Doxycycline]] 100 mg po bid x 14 days''''' 
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metronidazole]] 500 mg bid x 14 days''''' 
|-


| style="padding: 0 5px; font-size: 90%; background: #4479BA;" align=center | '''''Inpatient'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefoxitin]] 2 gm IV q6h''''' 
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Doxycycline]] 100 mg IV/po q12h''''' 
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Alternative Regimen'''''
|-
| style="padding: 0 5px; font-size: 90%; background: #4479BA;" align=center | '''''Outpatient'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 250 mg IM or IV x 1 dose'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Azithromycin]] 1 gm po weekly x 2 weeks'''''
|-

| style="padding: 0 5px; font-size: 90%; background: #4479BA;" align=center | '''''Inpatient'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Clindamycin]] 900 mg IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Gentamicin]] 2 mg/kg loading dose, then 1.5 mg/kg q8h or 4.5 mg/kg once/day'''''<br>then<br>'''''[[Doxycycline]] 100 mg po bid x 14 days'''''
|-

| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amp-Sulb]] 3 gm IV q6h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Doxycycline]] 100 mg IV/po q12h'''''
|-
|}
|}

====Follow-Up====

Patients should demonstrate substantial clinical improvement (e.g., defervescence; reduction in direct or rebound abdominal tenderness; and reduction in uterine, adnexal, and cervical motion tenderness) within 3 days after initiation of therapy. Patients who do not improve within this period usually require hospitalization, additional diagnostic tests, and surgical intervention.

If no clinical improvement has occurred within 72 hours after outpatient oral or parenteral therapy, further assessment should be performed. Subsequent hospitalization and an assessment of the antimicrobial regimen and diagnostics (including the consideration of diagnostic laparoscopy for alternative diagnoses) are recommended in women without clinical improvement. Women with documented chlamydial or gonococcal infections have a high rate of reinfection within 6 months of treatment. Repeat testing of all women who have been diagnosed with [[chlamydia]] or [[gonorrhea]] is recommended 3–6 months after treatment, regardless of whether their sex partners were treated. All women diagnosed with acute PID should be offered HIV testing.

===  Management of Sex Partners ===
Male partners of women who have PID often are asymptomatic.

Male sex partners of women with PID should be examined and treated if they had sexual contact with the patient during the 60 days preceding the patient’s onset of symptoms. If a patient’s last sexual intercourse was >60 days before onset of symptoms or diagnosis, the patient’s most recent sex partner should be treated. Patients should be instructed to abstain from sexual intercourse until therapy is completed and until they and their sex partners no longer have symptoms. Evaluation and treatment are imperative because of the risk for reinfection of the patient and the strong likelihood of urethral gonococcal or chlamydial infection in the sex partner. Male partners of women who have PID caused by ''C. trachomatis'' and/or ''N. gonorrhoeae'' frequently are asymptomatic.

Sex partners should be treated empirically with regimens effective against both of these infections, regardless of the etiology of PID or pathogens isolated from the infected woman. Even in clinical settings in which only women are treated, arrangements should be made to provide care or appropriate referral for male sex partners of women who have PID. Expedited partner treatment and enhanced patient referral are alternative approaches to treating male partners of women who have chlamydia or gonococcal infections.

===  Special Considerations ===

====  Pregnancy ====

Because of the high risk for maternal [[morbidity]] and preterm delivery, pregnant women who have suspected PID should be hospitalized and treated with parenteral [[antibiotics]].

====  HIV Infection ====

Differences in the clinical manifestations of PID between HIV-infected women and HIV-negative women have not been well delineated. In previous observational studies, HIV-infected women with PID were more likely to require surgical intervention; more comprehensive observational and controlled studies now have demonstrated that HIV-infected women with PID have similar symptoms when compared with uninfected controls, except they were more likely to have a tubo-ovarian abscess; both groups of women responded equally well to standard parenteral and oral antibiotic regimens. The microbiologic findings for HIV-positive and HIV-negative women were similar, except HIV-infected women had higher rates of concomitant''M. hominis'', candida, streptococcal, and HPV infections and HPV-related cytologic abnormalities. Regardlesss of these data, whether the management of immunodeficient HIV-infected women with PID requires more aggressive interventions (e.g., hospitalization or parenteral antimicrobial regimens) has not been determined.

====  Intrauterine Contraceptive Devices ====

[[IUD]]s are popular contraceptive choices for women. Both [[levonorgestrel]] and copper-containing devices are marketed in the United States. The risk for PID associated with [[IUD]]use is primarily confined to the first 3 weeks after insertion and is uncommon thereafter. Given the popularity of [[IUD]]s, practitioners might encounter PID in [[IUD]] users. Evidence is insufficient to recommend that the removal of [[IUD]]s in women diagnosed with acute PID. However, caution should be exercised if the [[IUD]] remains in place, and close clinical follow-up is mandatory. The rate of treatment failure and recurrent PID in women continuing to use an [[IUD]] is unknown, and no data have been collected regarding treatment outcomes by type of [[IUD]] (e.g., copper or levonorgestrel).

==References==
{{reflist|2}}
[[Category:Disease]]
[[Category:Infectious disease]]
[[Category:Gynecology]]
[[Category:Abdominal pain]]
[[Category:Sexually transmitted diseases]]
{{WH}}
{{WS}}